


PLPC™ PLATFORM

SOVEREIGN EXECUTIVE
BRIEF

✓ *On a global scale,
PLPC-DB is a All-New
Top-Tier non-cellular
cancer*

immunotherapy —

✓ *One of the strongest
and most advanced
secretome platforms
in existence.*



www.plpcplatform.org

1 PLPC PLATFORM

2 PLPC-DB

Personalized
Cancer
Immunotherapy

3 PLPC-NX

Immunocellular
4 Functional Lines

4 STIP™

NAM-aligned
Structural Traceability
& Immunophenotypic
Protocol

5 T-DEFENSE™

6 VITALIS™

7 REGENERA™

8 SPORT™

1. PLATFORM OVERVIEW (WHAT IT IS)

Module	Definition	Profile	Deployment
PLPC-DB™	Personalized Cancer Immunotherapy	· Intradermal · · At-home · Non-cellular · Non-genetic · NAM-aligned	Immediate use < 3 months (EA/CU/SAR) Animal-free · Phase 1–2–3 exempt · 10–15% cost · < 24 months
PLPC-NX™	4-Line GRAS Immunocellular	AM/PM architecture · AXIS model · 24 prototypes	Immediate GRAS status (notification- only)
STIP™	Regulatory -Tech Infrastructure	human ex vivo · Part 11 · CTD 5.3 engine	Regulatory modernization licensing Under NAM Guide Supports non- PD dossier

Ready to purchase
Bolt - On

✓ 2. SCIENTIFIC & REGULATORY VALIDATION

Validation Layer	Evidence
Real-world data	3,500 treated patients
Imaging	PET-FDG response patterns
Blood biomarkers	IL-6 · IL-10 · IFN-γ
Ex vivo NAM validation	STIP™ (human ex vivo, immunophenotypic mapping)
Peer-reviewed	5 Q1 open-access papers
Tier 1 Congress	11 oncology works (ASCO / ESMO / SITC / CAP25)
2 External audits	Freyr · Veristat
Documentation	Full CRF + CR / Full CTD (DB)

✓ 3. WHO SHOULD BUY THIS PLATFORM

Buyer Type	Relevant Asset	Strategic Reason
Sovereign Wealth Funds	DB · STIP · (bundle)	National oncology deployment · Health sovereignty · Global leadership
Ministries of Health	DB · STIP	Immediate therapeutic impact · Regulatory modernization
Big Pharma Oncology	DB · STIP	Pipeline diversification · Non-toxic immunotherapy class
Longevity & Wellness Funds	NX	100% GRAS Just Notification Ready to Market
Hospital/Health Networks	DB · NX	Immediate clinical or commercial integration

4. WHY BUY (BENEFITS)

Domain	PLPC-DB™ Benefit	PLPC-NX™ Benefit	STIP™ Benefit
Clinical impact	Non NCE Non PD Non Cell Immunotherapy	Anti-Tumor Soprt	Lower Costs Shorter Timeline
Operational	No cold chain · Intradermal · At-Home	GRAS · No IND	Part 11 traceability
Regulatory	CTD-ready · EA/CU routes	No friction	NAM- aligned
Commercial	Sovereign-scale oncology asset	Ready	Licensing revenue
Strategic	Fist-in-Class 2 Pre FDA Audits	Multi- line	2022 Act 2.0

5. FULL PLATFORM VALUE (BUNDLE)

Asset	SMP V	CCV	PEEV
PLPC-DB™	1.20B	400 M	240 M
PLPC-NX™	300M	180 M	108 M
STIP™	350M	120 M	120 M

6. PLPC-DB VALUATION

Comparative Advantage	Amount
Buying separately (CCV sum)	700M
Buying full bundle (PEEV)	420M
Total advantage	280M



Concept rendering — not final packaging.

7. NX: AREA & LINE VALUATIONS

Area	SMPV	CCV	PEEV
TheraSupport	140M	90M	54M
Wellness	140M	90M	54M

NX Lines

Line	SMPV	CCV	PEEV
T-Defense™	80M	55M	33M
Regenera™	70M	45M	27M
Vitalis™	70M	40M	24M
Sport™	70M	40M	24M



8. ENTRY OPTIONS (INSTITUTIONAL MODELS)

Entry Form	Applies To	Description
80% Acquisition	DB · NX · STIP	Majority control for sovereign funds / pharma
NewCo Formation	DB · NX	Buyer capital + OGRD IP and governance
Hybrid Equity 30/70	DB · NX · STIP	Strategic or phased entry
Licensing	STIP	Sovereign, CRO,

“Referential only; final terms subject to executed Term Sheets.”



9. STRATEGIC ENTRY MAP

Buyer Objective	Recommended Path	Capital Window
National oncology leadership	PLPC-DB™ (80%)	320M
Regulatory modernization	STIP™ (PEEV)	120M
Rapid commercialization	PLPC-NX™ (80%)	144M
Tactical access	NX Area or Line	24–54M
Multi-module synergy	NX NewCo + 10% DB + STIP License	204M (PEEV)

10. EXECUTIVE CLOSING

Category	Status
Scientific maturity	Complete (3,500 patients, PET-FDG, IL-serology)
Regulatory readiness	Full CTD (DB), NAM/STIP validation
Legal defensibility	Freshfields · WilmerHale · Al Tamimi
Operational readiness	No cold chain · Intradermal · At-Home · Each Cancer tye
Transaction readiness	SMPV/CCV/PEEV fixed · Areas · Lines · Bundle
Institutional relevance	Sovereign funds · Ministries · Pharma · CROs